# Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.

> **NCT04232917** · PHASE4 · RECRUITING · sponsor: **Labo'Life** · enrollment: 284 (estimated)

## Conditions studied

- Human Papilloma Virus

## Interventions

- **DRUG:** 2LPAPI®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04232917
- **Lead sponsor:** Labo'Life
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-17
- **Primary completion:** 2027-03-15
- **Final completion:** 2027-10-30
- **Target enrollment:** 284 (ESTIMATED)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04232917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04232917, "Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04232917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*